Search

Your search keyword '"Cobelli F"' showing total 1,007 results
Start Over Author "Cobelli F" Language english
1,007 results on '"Cobelli F"'

1. Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial

Author

Fiorino, C., Palumbo, D., Mori, M., Palazzo, G., Pellegrini, A.E., Albarello, L., Belardo, A., Canevari, C., Cossu, A., Damascelli, A., Elmore, U., Mazza, E., Pavarini, M., Passoni, P., Puccetti, F., Slim, N., Steidler, S., Del Vecchio, A., Di Muzio, N.G., Chiti, A., Rosati, R., and De Cobelli, F.

Published
2024
Full Text
View/download PDF

3. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author

Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Å., Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.

Published
2022
Full Text
View/download PDF

4. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Author

Rimini, M., Rimassa, L., Ueshima, K., Burgio, V., Shigeo, S., Tada, T., Suda, G., Yoo, C., Cheon, J., Pinato, D.J., Lonardi, S., Scartozzi, M., Iavarone, M., Di Costanzo, G.G., Marra, F., Soldà, C., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Pressiani, T., Nishida, N., Iwamoto, H., Sakamoto, N., Ryoo, B.-Y., Chon, H.J., Claudia, F., Niizeki, T., Sho, T., Kang, B., D’Alessio, A., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Ochi, H., Yasuda, S., Toyoda, H., Ogawa, C., Nishimur, T., Hatanaka, T., Kakizaki, S., Shimada, N., Kawata, K., Tanaka, T., Ohama, H., Nouso, K., Morishita, A., Tsutsui, A., Nagano, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Naganuma, A., Koizumi, Y., Nakamura, S., Joko, K., Iijima, H., Hiasa, Y., Pedica, F., De Cobelli, F., Ratti, F., Aldrighetti, L., Kudo, M., Cascinu, S., and Casadei-Gardini, A.

Published
2022
Full Text
View/download PDF

5. 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours

Author

Mapelli, P., Bezzi, C., Palumbo, D., Canevari, C., Ghezzo, S., Samanes Gajate, A. M., Catalfamo, B., Messina, A., Presotto, L., Guarnaccia, A., Bettinardi, V., Muffatti, F., Andreasi, V., Schiavo Lena, M., Gianolli, L., Partelli, S., Falconi, M., Scifo, P., De Cobelli, F., and Picchio, M.

Published
2022
Full Text
View/download PDF

6. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Author

Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, and Casadei-Gardini A

Subjects
hepatocarcinoma, sorafenib, lenvatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De Cobelli,23 Luca Aldrighetti,20 Stefano Cascinu,1,23 Andrea Casadei-Gardini1,23 1Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 2Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; 3Department of Hepatology, Naples, 80131, Italy; 4Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy; 5Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 6Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 7Department of Oncology and Palliative Care, Cardinale Hospital, Naples, Italy; 8Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 9Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 10Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 11Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, 90127, Italy; 12Internal Medicine, Infermi Hospital, Faenza (AUSL ROMAGNA), Ravenna, Italy; 13Department of Oncology, Campus Bio Medico, Roma, Italy; 14Hepatology Unit, Internal Medicine, Area Stabiese Hospital, Naples, Italy; 15Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, Modena, 4121, Italy; 16Department of General Surgery and Emergency Surgery, Cardinale Hospital, Tricase, Italy; 17Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, Italy; 18Liver Center, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 19Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 20Hepatobiliary Surgery Division, Liver Center, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 21Department of Experimental Oncology, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 22Department of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 23School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, ItalyCorrespondence: Andrea Casadei-GardiniDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina n. 60, Milan, ItalyEmail casadeigardini@gmail.comBackground: Lenvatinib has been approved in Italy since October 2019 as a first-line therapy for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness and safety of lenvatinib are not available in our region. To fill this gap, we performed a multicentric analysis of the real-world treatment outcomes with the propensity score matching in a cohort of Italian patients with unresectable HCC who were treated with either sorafenib or lenvatinib.Aims and Methods: To evaluate the effectiveness of sorafenib and lenvatinib as primary treatment of advanced HCC in clinical practice we performed a multicentric analysis of the treatment outcomes of 288 such patients recruited in 11 centers in Italy. A propensity score was used to mitigate confounding due to referral biases in the assessment of mortality and progression-free survival.Results: Over a follow-up period of 11 months the Cox regression model showed 48% reduction of death risk for patients treated with lenvatinib (95% CI: 0.34– 0.81; p = 0.0034), compared with those treated with sorafenib. The median PFS was 9.0 and 4.9 months for lenvatinib and sorafenib arm, respectively. Patients treated with lenvatinib showed a higher percentage of response rate (29.4% vs 2.8%; p < 0.00001) compared with patients treated with sorafenib. Sorafenib was shown to be correlated with more HFSR, diarrhea and fatigue, while lenvatinib with more hypertension and fatigue.Conclusion: Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.Keywords: hepatocarcinoma, sorafenib, lenvatinib

Published
2021

17. Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group

Author

Mauri G., Bernardi S., Palermo A., Cesareo R., Papini E., Solbiati L., Barbaro D., Monti S., Deandrea M., Fugazzola L., Gambelunghe G., Negro R., Spiezia S., Stacul F., Sconfienza L. M., Cavallaro M., Achille G., Cantisani V., Cozzaglio L., Crescenzi A., De Cobelli F., Garberoglio R., Giugliano G., Persani L., Raggiunti B., Seregni E., Van Doorne D., Frasoldati A., Carzaniga C., Lombardi C. P., Papi G., Guglielmi R., Orsi F., Cervelli R., Barbieri C., Trimboli P., Monzani D., Mauri G., Bernardi S., Palermo A., Cesareo R., Papini E., Solbiati L., Barbaro D., Monti S., Deandrea M., Fugazzola L., Gambelunghe G., Negro R., Spiezia S., Stacul F., Sconfienza L.M., Cavallaro M., Achille G., Cantisani V., Cozzaglio L., Crescenzi A., De Cobelli F., Garberoglio R., Giugliano G., Persani L., Raggiunti B., Seregni E., Van Doorne D., Frasoldati A., Carzaniga C., Lombardi C.P., Papi G., Guglielmi R., Orsi F., Cervelli R., Barbieri C., Trimboli P., Monzani D., Mauri, G., Bernardi, S., Palermo, A., Cesareo, R., Papini, E., Solbiati, L., Barbaro, D., Monti, S., Deandrea, M., Fugazzola, L., Gambelunghe, G., Negro, R., Spiezia, S., Stacul, F., Sconfienza, L. M., Cavallaro, M., Achille, G., Cantisani, V., Cozzaglio, L., Crescenzi, A., De Cobelli, F., Garberoglio, R., Giugliano, G., Persani, L., Raggiunti, B., Seregni, E., Van Doorne, D., Frasoldati, A., Carzaniga, C., Lombardi, C. P., Papi, G., Guglielmi, R., Orsi, F., Cervelli, R., Barbieri, C., Trimboli, P., and Monzani, D.

Subjects
Patient, Ethanol, Endocrinology, Diabetes and Metabolism, Laser, Thyroid Function Tests, Thyroid Function Test, Endocrinology, Treatment Outcome, Physician, Radiofrequency, Physicians, Practice Guidelines as Topic, Catheter Ablation, Humans, Microwave, Thyroid nodule, Thyroid Nodule, Human
Abstract

Purpose In this paper, the members of the Italian Working Group on Minimally-Invasive Treatments of the Thyroid (MITT group) aim to summarize the most relevant information that could be of help to referring physicians and that should be provided to patients when considering the use of MITT for the treatment of benign thyroid nodules. Methods An interdisciplinary board of physicians with specific expertise in the management of thyroid nodules was appointed by the Italian MITT Group. A systematic literature search was performed, and an evidence-based approach was used, including also the knowledge and the practical experience of the panelists to develop the paper. Results The paper provides a list of questions that are frequently asked by patients to operators performing MITT, each with a brief and detailed answer and more relevant literature references to be consulted. Conclusions This paper summarizes the most relevant information to be provided to patients and general practitioners/referring physicians about the use of MITT for the treatment of benign thyroid nodules.

Published
2022

21. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Author

De Luca G., Cavalli G., Campochiaro C., Della-Torre E., Angelillo P., Tomelleri A., Boffini N., Tentori S., Mette F., Farina N., Rovere-Querini P., Ruggeri A., D'Aliberti T., Scarpellini P., Landoni G., De Cobelli F., Paolini J. F., Zangrillo A., Tresoldi M., Trapnell B. C., Ciceri F., Dagna L., DE LUCA , GIACOMO, De Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Farina, N., Rovere-Querini, P., Ruggeri, A., D'Aliberti, T., Scarpellini, P., Landoni, G., De Cobelli, F., Paolini, J. F., Zangrillo, A., Tresoldi, M., Trapnell, B. C., Ciceri, F., Dagna, L., and DE LUCA, Giacomo

Subjects
Mechanical ventilation, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Immunology, medicine.disease, Article, Blockade, Single centre, Pneumonia, Mavrilimumab, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Prospective cohort study, Adverse effect, business
Abstract

Summary Background Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. Methods This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily. Findings Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52–58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53–67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11] vs 19 days [11 to >28], p=0·0001). By day 28, one (8%) patient in the mavrilimumab group progressed to mechanical ventilation compared with nine (35%) patients in the control group who progressed to mechanical ventilation or died (p=0·14). By day 14, fever resolved in ten (91%) of 11 febrile patients in the mavrilimumab group, compared with 11 (61%) of 18 febrile patients in the control group (p=0·18); fever resolution was faster in mavrilimumab recipients versus controls (median time to resolution 1 day [IQR 1 to 2] vs 7 days [3 to >14], p=0·0093). Mavrilimumab was well tolerated, with no infusion reactions. Three (12%) patients in the control group developed infectious complications. Interpretation Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing. Funding IRCCS San Raffaele Scientific Institute.

Published
2020

22. Residual lung damage following ARDS in COVID-19 ICU survivors

Author

Compagnone N., Palumbo D., Cremona G., Vitali G., De Lorenzo R., Calvi M. R., Del Prete A., Baiardo Redaelli M., Calamara S., Belletti A., Steidler S., Conte C., Zangrillo A., De Cobelli F., Rovere-Querini P., Monti G., Castellani J., Cilla M., Cinel E., Di Tomasso N., Falbo E., Faustini C., Fedrizzi M., Ferrante M., Fresilli S., Landoni G., Magnaghi C., Maimeri N., Martinenghi S., Moizo E., Mucci M., Velati M., Compagnone, N., Palumbo, D., Cremona, G., Vitali, G., De Lorenzo, R., Calvi, M. R., Del Prete, A., Baiardo Redaelli, M., Calamara, S., Belletti, A., Steidler, S., Conte, C., Zangrillo, A., De Cobelli, F., Rovere-Querini, P., Monti, G., Castellani, J., Cilla, M., Cinel, E., Di Tomasso, N., Falbo, E., Faustini, C., Fedrizzi, M., Ferrante, M., Fresilli, S., Landoni, G., Magnaghi, C., Maimeri, N., Martinenghi, S., Moizo, E., Mucci, M., and Velati, M.

Subjects
Adult, Male, ARDS, chest CT scan, medicine.medical_treatment, critically ill patients, pulmonary function tests, Pulmonary function testing, COVID‐19, Interquartile range, DLCO, Intensive care, follow-up, Medicine, Humans, Survivors, Lung, Research Articles, Tidal volume, intensive care, follow‐up, Mechanical ventilation, Respiratory Distress Syndrome, pulmonary fibrosis, business.industry, SARS-CoV-2, COVID-19, General Medicine, respiratory system, acute respiratory distress syndrome, Middle Aged, medicine.disease, respiratory tract diseases, Intensive Care Units, Anesthesiology and Pain Medicine, medicine.anatomical_structure, Anesthesia, business, Research Article
Abstract

Background Coronavirus disease 2019 acute respiratory distress syndrome (COVID‐19 ARDS) is a disease that often requires invasive ventilation. Little is known about COVID‐19 ARDS sequelae. We assessed the mid‐term lung status of COVID‐19 survivors and investigated factors associated with pulmonary sequelae. Methods All adult COVID‐19 patients admitted to the intensive care unit from 25th February to 27th April 2020 were included. Lung function was evaluated through chest CT scan and pulmonary function tests (PFT). Logistic regression was used to identify predictors of persisting lung alterations. Results Forty‐nine patients (75%) completed lung assessment. Chest CT scan was performed after a median (interquartile range) time of 97 (89–105) days, whilst PFT after 142 (133–160) days. The median age was 58 (52–65) years and most patients were male (90%). The median duration of mechanical ventilation was 11 (6–16) days. Median tidal volume/ideal body weight (TV/IBW) was 6.8 (5.71–7.67) ml/Kg. 59% and 63% of patients showed radiological and functional lung sequelae, respectively. The diffusion capacity of carbon monoxide (DLCO) was reduced by 59%, with a median per cent of predicted DLCO of 72.1 (57.9–93.9) %. Mean TV/IBW during invasive ventilation emerged as an independent predictor of persistent CT scan abnormalities, whilst the duration of mechanical ventilation was an independent predictor of both CT and PFT abnormalities. The extension of lung involvement at hospital admission (evaluated through Radiographic Assessment of Lung Edema, RALE score) independently predicted the risk of persistent alterations in PFTs. Conclusions Both the extent of lung parenchymal involvement and mechanical ventilation protocols predict morphological and functional lung abnormalities months after COVID‐19.

Published
2022

26. Re: MultiparametricMagnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study

Author

Necchi, A., Bandini, M., Calareso, G., Raggi, D., Pederzoli, F., Fare, E., Colecchia, M., Marandino, L., Bianchi, M., Gallina, A., Colombo, R., Fossati, N., Gandaglia, G., Capitanio, U., Deho, F., Giannatempo, P., Luciano, R., Salonia, A., Madison, R., Ali, S. M., Chung, J. H., Ross, J. S., Briganti, A., Montorsi, F., De Cobelli, F., and Messina, A.

Subjects
Male, Urethral Neoplasms, Urethra, Urology, Urinary Bladder, Humans, Penis
Published
2022

27. Dynamic changes of mitral valve annulus geometry at preprocedural CT: relationship with functional classes of regurgitation

Author

Palmisano A., Nicoletti V., Colantoni C., Monti C. B., Pannone L., Vignale D., Darvizeh F., Agricola E., Schaffino S., De Cobelli F., Esposito A., Palmisano, A., Nicoletti, V., Colantoni, C., Monti, C. B., Pannone, L., Vignale, D., Darvizeh, F., Agricola, E., Schaffino, S., De Cobelli, F., and Esposito, A.

Subjects
Mitral valve, Planning techniques, Computed tomography angiography, Heart valve prosthesis, Mitral valve insufficiency
Abstract

Background: We investigated mitral valve annular geometry changes during thecardiac cycle in patients with severe mitral regurgitation (MR) who underwent cardiac computed tomography angiography (CCTA) prior to percutaneous mitral valve replacement or annuloplasty. Methods: Fifty-one patients with severe MR and high surgical risk (Carpentier classification: 3 type I, 16 type II, 16 type IIIa, 16 type IIIb) underwent multiphase electrocardiographically gated (0–90%) CCTA, using a second generation dual-source CT scanner, as pre-procedural planning. Twenty-one patients without MR served as controls. The mitral valve annulus was segmented every 10% step of the R-R interval, according to the D-shaped segmentation model, and differences among groups were analysed by t-test or ANOVA. Results: Mitral annular area and diameters were larger in MR patients compared to controls, particularly in type II. Mitral annular area varied in MR patients throughout the cardiac cycle (mean ± standard deviation of maximum and minimum area 15.6 ± 3.9 cm2versus 13.0 ± 3.5 cm2, respectively; p = 0.001), with greater difference between annular areas versus controls (2.59 ± 1.61 cm2 and 1.98 ± 0.6 cm2, p < 0.001). The largest dimension was found in systolic phases (20–40%) in most of MR patients (n = 27, 53%), independent of Carpentier type (I: n = 1, 33%; II: n = 10, 63%; IIIa: n = 8, 50%; IIIb: n = 8, 50%), andin protodiastolic phases (n = 14, 67%) for the control group. Conclusions: In severe MR, mitral annular area varied significantly throughout the cardiac cycle, with a tendency towards larger dimensions in systole.

Published
2021

31. A0901 - First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)

Author

Mercinelli, C., Basile, G., Raggi, D., Cigliola, A., Tateo, V., Patanè, D.A., Crupi, E., Costa De Padua, T., Colecchia, M., Colombo, R., Moschini, M., Re, C., Avesani, G., Brembilla, G., De Cobelli, F., Briganti, A., Pavlick, D.C., Ross, J.S., Montorsi, F., and Necchi, A.

Published
2024
Full Text
View/download PDF

32. A0818 - A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series

Author

Stabile, A., Leni, R., Quarta, L., Mazzone, E., Cannoletta, D., Gandaglia, G., Pellegrino, F., Sorce, G., Pellegrino, A., Russo, T., Cosenza, M., Pennella, R., Brembilla, G., De Cobelli, F., Cucchiara, V., Scuderi, S., Robesti, D., Karnes, R.J., Roupret, M., Montorsi, F., and Briganti, A.

Published
2024
Full Text
View/download PDF

34. A0716 - Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series

Author

Quarta, L., Stabile, A., Barletta, F., Mazzone, E., Cannoletta, D., Pellegrino, F., Sorce, G., Pellegrino, A., Cucchiara, V., Scuderi, S., Robesti, D., Leni, R., Bianchi, M., Longoni, M., Scilipoti, P., De Cobelli, F., Esposito, A., Gandaglia, G., Montorsi, F., and Briganti, A.

Published
2024
Full Text
View/download PDF

36. A0436 - PSMA radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Updated results of a planned interim analysis of a prospective phase 2 study

Author

Quarta, L., Mazzone, E., Gandaglia, G., Stabile, A., Pellegrino, A., Cucchiara, V., Barletta, F., Scuderi, S., Robesti, D., Leni, R., Cannoletta, D., Zaurito, P., Samanes Gajate, A.M., Picchio, M., Chiti, A., Brembilla, G., De Cobelli, F., Van Oosterom, M.N., Van Leeuwen, F.W.B., Montorsi, F., and Briganti, A.

Published
2024
Full Text
View/download PDF

38. P329 - How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series

Author

Pellegrino, A., Stabile, A., Quarta, L., Barletta, F., Mazzone, E., Cannoletta, D., Pellegrino, F., Sorce, G., Cucchiara, V., Scuderi, S., Robesti, D., Leni, R., Cirulli, G.O., Longoni, M., Scilipoti, P., De Angelis, M., De Cobelli, F., Esposito, A., Gandaglia, G., Montorsi, F., and Briganti, A.

Published
2024
Full Text
View/download PDF

39. P311 - Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

Author

Quarta, L., Stabile, A., Barletta, F., Mazzone, E., Cannoletta, D., Pellegrino, F., Sorce, G., Pellegrino, A., Cucchiara, V., Scuderi, S., Robesti, D., Leni, R., Gandaglia, G., Bianchi, M., De Cobelli, F., Brembilla, G., Roupret, M., Karnes, R.J., Montorsi, F., and Briganti, A.

Published
2024
Full Text
View/download PDF

40. P145 - Preoperative or intraoperative renal biopsy increases the accuracy in predicting lymph node invasion in patients with renal cell carcinoma

Author

Belladelli, F., Re, C., Cei, F., Musso, G., Rosiello, G., Cignoli, D., Canibus, D., Fiorio, F., Bertini, R., Salonia, A., De Cobelli, F., Brembilla, G., Roupret, M., Esposito, A., Palmisano, A., Piccolo, C., Gambirasio, M., Lucianò, R., Tenace, N., Briganti, A., Montorsi, F., Larcher, A., and Capitanio, U.

Published
2024
Full Text
View/download PDF

41. P144 - Renal biopsy does not affect mortality in renal mass patients when confronted with upfront surgery: A propensity score adjusted analysis

Author

Belladelli, F., Re, C., Cei, F., Musso, G., Rosiello, G., Cignoli, D., Piccolo, C., Salerno, L., Iannace, F., Canibus, D., Fiorio, F., Matloob, R., Bertini, R., Salonia, A., De Cobelli, F., Brembilla, G., Gusmini, S., Guazzarotti, G., Gambirasio, M., Briganti, A., Montorsi, F., Larcher, A., and Capitanio, U.

Published
2024
Full Text
View/download PDF

42. P128 - Surveillance interruption and need for active treatment in Von Hippel-Lindau disease: implications for clinical management and trial design

Author

Cei, F., Re, C., Belladelli, F., Salerno, L., Falini, A., Calloni, S., De Cobelli, F., Guazzarotti, G., Mortini, P., Capitanio, J.F., Bailo, M., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Muffatti, F., Castellino, L., Piccioni, L.O., Battista, R.A., Rowe, I., Montorsi, F., Capitanio, U., Larcher, A., and Salonia, A.

Published
2024
Full Text
View/download PDF

45. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Author

Campochiaro C., Della-Torre E., Cavalli G., De Luca G., Ripa M., Boffini N., Tomelleri A., Baldissera E., Rovere-Querini P., Ruggeri A., Monti G., De Cobelli F., Zangrillo A., Tresoldi M., Castagna A., Dagna L (TOCI-RAF Study Group), Landoni G, DELLA TORRE , EMANUEL, Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., Tomelleri, A., Baldissera, E., Rovere-Querini, P., Ruggeri, A., Monti, G., De Cobelli, F., Zangrillo, A., Tresoldi, M., Castagna, A., Dagna, L (TOCI-RAF Study Group), Landoni, G, and DELLA TORRE, Emanuel

Subjects
Male, musculoskeletal diseases, medicine.medical_specialty, Multivariate analysis, Coronavirus disease 2019 (COVID-19), Efficacy, Pneumonia, Viral, macromolecular substances, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Antiviral Agents, Article, Betacoronavirus, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Medical microbiology, Internal medicine, Intensive care, Internal Medicine, Humans, Medicine, 030212 general & internal medicine, skin and connective tissue diseases, Pandemics, Aged, Retrospective Studies, business.industry, Interleukin-6, Standard treatment, Oxygen Inhalation Therapy, COVID-19, Retrospective cohort study, Middle Aged, Receptors, Interleukin-6, Coronavirus, Outcome and Process Assessment, Health Care, chemistry, Italy, Cohort, Female, Safety, Coronavirus Infections, Respiratory Insufficiency, business
Abstract

Highlight • This is the first study comparing tocilizumab to standard of care in severe COVID-19 • Tocilizumab in severe COVID-19 patients did influence 28-day clinical outcomes • Tocilizumab safety was safisfactory except for ICU-admitted patients, Background : Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. Methods : We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. Results : 65 patients were included, 32 were of whose treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. Conclusions : At day 28, clinical improvement and mortality were not statistically significant different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.

Published
2020

46. Esophagus and Stomach: Is There a Role for MR Imaging?

Author

De Cobelli F., Palumbo D., Albarello L., Rosati R., Giganti F., De Cobelli, F., Palumbo, D., Albarello, L., Rosati, R., and Giganti, F.

Subjects
Magnetic resonance imaging, Staging, Prognosi, Esophageal cancer, Gastric cancer, Treatment response
Abstract

MR imaging has been increasingly used in the diagnostic work-up of benign and malignant conditions of the gastroesophageal tract. The use of an adequate MR imaging protocol is crucial, although standardization of imaging studies is still far from being implemented. Research on MR imaging-based biomarkers show promising results in assessing tumor aggressiveness and prognosis, and in the evaluation of response to treatment, both in esophageal and gastric cancers.

Published
2020

49. Clinical indications for cardiac computed tomography. From the Working Group of the Cardiac Radiology Section of the Italian Society of Medical Radiology (SIRM)

Author

di Cesare, E., Carbone, I., Carriero, A., Centonze, M., De Cobelli, F., De Rosa, R., Di Renzi, P., Esposito, A., Faletti, R., Fattori, R., Francone, M., Giovagnoni, A., La Grutta, L., Ligabue, G., Lovato, L., Marano, R., Midiri, M., Natale, L., Romagnoli, A., Russo, V., Sardanelli, F., and Cademartiri, F.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results